Physician profile
Devi Meyyappan
NPI 1619138336
$4,265.94
in general payments reported to CMS, 2019-2025
11 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.95 · 2021: $150 · 2022: $167 · 2023: $2,361 · 2024: $226 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,739 · Consulting Fee: $1,263 · Food and Beverage: $830 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,739.49 |
| Consulting Fee | $1,262.50 |
| Food and Beverage | $829.98 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,889.47 | 2023 | Keytruda |
| Janssen Biotech, INC. | $1,395.50 | 2022-2025 | Erleada |
| Amgen INC. | $270.55 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $142.01 | 2023-2024 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $124.99 | 2024 | Tagrisso |
| Mirati Therapeutics, INC. | $117.41 | 2023 | Krazati |
| Incyte Corporation | $117.41 | 2023 | Jakafi |
| Seagen INC. | $99.95 | 2020 | |
| Novartis Pharmaceuticals Corporation | $83.69 | 2024 | |
| Lilly USA, LLC | $13.04 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devi Meyyappan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.